Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation (NASDAQ: RGEN) is a global life sciences company headquartered in Waltham, Massachusetts, focused on bioprocessing technologies and systems that support the manufacturing of biological drugs. This news page aggregates company announcements, earnings updates, product launches and strategic developments directly related to Repligen’s operations in bioprocessing.
According to its public communications, Repligen serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs), with core focus areas in Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. News items often highlight how these focus areas evolve through new products, partnerships and technology integrations.
Investors and industry followers can use this page to review earnings press releases and related Form 8-K announcements, which cover quarterly financial results, guidance updates and commentary on demand trends across Repligen’s franchises and geographies. The company’s releases also discuss the use of non-GAAP financial measures and provide reconciliations to GAAP results.
Repligen’s news flow additionally includes product and technology updates, such as the launch of new chromatography resins in its proteins portfolio and introductions of equipment in areas like mixing and process analytics. Strategic partnerships, including its collaboration with Novasign to integrate machine learning and modeling workflows into Repligen filtration systems, are another recurring theme.
Governance and leadership developments, such as Board chair transitions and senior finance appointments disclosed via press releases and Form 8-K filings, also appear in the news stream. By checking this page regularly, readers can follow how Repligen describes its progress in bioprocessing technology leadership, digitalization initiatives, and its engagement with the biopharmaceutical and CDMO sectors.
Repligen Corporation (NASDAQ:RGEN) will release its third quarter 2021 financial results on October 28, 2021, prior to market open. A conference call will follow at 8:30 a.m. EDT to discuss business updates and results for the three- and nine-month periods ending September 30, 2021. Interested parties can access the call by dialing specific numbers based on their location. Repligen, a life sciences company, focuses on innovative bioprocessing technologies for biopharmaceutical manufacturers globally. More details can be found on their website.
Repligen Corporation (NASDAQ:RGEN) has entered into a definitive agreement to acquire Avitide Inc. for approximately $150 million. The deal includes $75 million in cash and $75 million in Repligen common stock, alongside performance-based earnouts over three years. This acquisition aims to enhance Repligen’s Proteins business, particularly in affinity ligand solutions for gene therapy, with Avitide expected to contribute about $10 million in revenue in 2022 and positively impact adjusted earnings per share in 2023.
Repligen Corporation (NASDAQ:RGEN) and Navigo Proteins GmbH announced the successful development of a novel protein A ligand called NGL-Impact A Hi pH. This innovative ligand addresses critical challenges in purifying pH sensitive antibodies and Fc-fusion proteins, notably reducing antibody aggregation during purification. Customer evaluations showcased a two-fold decrease in aggregate formation while maintaining high dynamic binding capacity. The ligand is set for commercialization via a new resin later this year, potentially offering significant cost and time savings for developers in the biopharmaceutical industry.
Repligen Corporation (NASDAQ:RGEN) reported Q2 2021 revenue of $163.0 million, achieving an 86% year-over-year growth and 69% organic growth. The company raised its revenue guidance for 2021 to $625-$645 million from previous estimates of $565-$590 million. The acquisition of Polymem S.A. further enhances Repligen's capabilities. Key financial metrics include a GAAP EPS of $0.64 and adjusted EPS of $0.79 for the quarter. The company anticipates a gross margin of 59%-60% for the year, reflecting ongoing strong performance.
Repligen Corporation (NASDAQ:RGEN) will report its Q2 2021 financial results on July 27, 2021. A press release will be issued before the market opens, followed by a conference call at 8:30 a.m. EDT to discuss financial results for the three- and six-month periods ending June 30, 2021. Domestic callers can dial (844) 274-3999, while international callers can use (412) 317-5607. The call will also be available via a webcast on the company’s Investor Relations webpage, with archived access provided as well.
Repligen Corporation (NASDAQ:RGEN) announced its acquisition of Polymem S.A., a French specialist in hollow fiber membranes, on June 22, 2021. This acquisition enhances Repligen's production capabilities and R&D expertise, positioning it to meet growing demand in both industrial and bioprocessing markets. The deal is expected to close in Repligen's third fiscal quarter of 2021, utilizing cash reserves of approximately $711 million as of March 31, 2021. Polymem's leadership will remain in place post-acquisition, aiming to expand market reach and growth opportunities.
Repligen Corporation (NASDAQ:RGEN) has announced its participation in two virtual investor conferences. CEO Tony J. Hunt will join the William Blair 41st Annual Growth Stock Conference on June 1 at 1:40 p.m. EST and the Jefferies Virtual Healthcare Conference on June 3 at 2:30 p.m. EST. These discussions will be available via live webcast and can be replayed afterward. Repligen focuses on developing innovative bioprocessing technologies for biopharmaceutical manufacturers globally.
Repligen Corporation (NASDAQ:RGEN) reported a remarkable first-quarter revenue of $142.8 million, reflecting an 88% year-over-year increase and 69% organic growth. Key growth drivers included COVID-related demand contributing 25% of total revenue, alongside a 31% increase in its non-COVID base business. The company also revised its 2021 financial outlook, expecting total revenue between $565-$590 million, significantly up from previous guidance. GAAP EPS rose to $0.52 from $0.18 year-on-year. Adjusted EPS reached $0.68, compared to $0.32 in Q1 2020.
Repligen Corporation (NASDAQ:RGEN) will report its Q1 2021 financial results on May 4, 2021, with a press release issued before market opening. A conference call will be held at 8:30 a.m. EDT to discuss the results for the three-month period ending March 31, 2021. Callers can join via toll-free numbers for domestic and international participants, with no passcode required. The event will also be available for replay. As a leading life sciences company, Repligen specializes in innovative bioprocessing technologies aimed at enhancing biopharmaceutical manufacturing efficiency.
Repligen Corporation (NASDAQ:RGEN) will present virtually at the KeyBanc Life Science and MedTech Investor Forum on March 23-24, 2021. CEO Tony Hunt will participate in a fireside chat on March 24 at 9:15 a.m. EDT. The discussion will be available via live webcast on the company's Investor Relations website, with a replay accessible for a limited time post-event. Repligen specializes in innovative bioprocessing technologies, serving biopharmaceutical developers and contract manufacturers globally, with headquarters in Waltham, Massachusetts.